Predicting the response to Terlipressin:
Research type
Research Study
Full title
Predicting the Response to Terlipressin: An observational case-control prospective clinical study
IRAS ID
246381
Contact name
Kevin P Moore
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
2 years, 11 months, 31 days
Research summary
The development of hepatorenal syndrome (HRS) or acute kidney injury in cirrhosis has a poor prognosis, and treatment with terlipressin is effective in ~40% of patients. The development of HRS is due to several factors which include a lowering of mean arterial pressure, activation of the renal sympathetic nervous system, both of which are improved by terlipressin, as well as the development of cirrhotic cardiomyopathy and increased formation of various vasoactive mediators. It is not known whether terlipressin has an effect on either cirrhotic cardiomyopathy or the formation of vasoactive mediators, both of which may be directly related to the development of oxidative or nitrative stress. From a clinical point of view, it is difficult to know which patients will respond to terlipressin, and what phenotype predicts responsiveness? Part of the problem is that while retrospective data analysis have been conducted, no studies have directly addressed this prospectively, and nor have they applied such rigor using the new updated International Ascites Club Guidelines. This study will aim to correct that imbalance by collecting data before, during and after therapy with terlipressin for hepatorenal syndrome. The study will evaluate 30 patients with Hepatorenal Syndrome as defined by current International Ascites Club Guidelines.
REC name
London - Harrow Research Ethics Committee
REC reference
18/LO/1631
Date of REC Opinion
29 Nov 2018
REC opinion
Further Information Favourable Opinion